Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech

As of 2026-09-28, XBI returned 81.5% over one year versus 27.8% for FHLC, but had a much deeper five-year maximum drawdown: 63.9% versus 17.7%. FHLC charges a 0.08% expense ratio and yields 1.2%, compared with XBI’s 0.35% expense ratio and 0.3% yield. The article presents FHLC as the broader, lower-volatility option and XBI as the higher-risk biotech-focused fund.

Analysis

The expense gap is not the decision variable: a 27 bp annual fee difference is small beside the funds’ very different factor and drawdown exposures. FHLC behaves more like a large-cap healthcare allocation, with meaningful dependence on its largest pharmaceutical positions; XBI is a higher-beta, more equal-weighted bet on smaller biotech outcomes and risk appetite. XBI’s strong trailing performance may attract momentum flows, but extrapolating it is risky: clinical and regulatory outcomes are lumpy, and tighter financing conditions can pressure smaller firms even without a broad healthcare selloff.

Near term, rates, risk appetite, and clinical readouts are likely to dominate relative performance; over 6–18 months, company-specific pipeline results and large-cap drug-cycle concentration matter more than the fee difference. A contrarian point: the five-year drawdown statistic is a poor standalone reason to avoid XBI, while the sharp recent rally is not evidence that its risk has fallen. The supplied data do not establish current valuations, breadth of the rally, or what drove returns; verify those before sizing a directional view.

Key Decisions for Investors

• Treat FHLC as the lower-volatility healthcare core and XBI as a tactical satellite, not interchangeable sector substitutes. Avoid sizing either from the expense ratio alone.
• No high-conviction pair trade on this comparison alone. If seeking a relative-value expression, consider a modest FHLC-over-XBI position only if biotech momentum breadth weakens or risk appetite deteriorates; reassess if XBI continues outperforming across a broad set of holdings and financing conditions remain supportive.
• For XBI, monitor clinical/regulatory readouts, biotech issuance and funding conditions, and whether gains are broad-based rather than concentrated in a few names. For FHLC, monitor earnings and guidance from its largest holdings; concentration there can make the broad-sector label misleading.
• Falsify a cautious XBI view if subsequent results and guidance support broad-based earnings improvement and XBI sustains relative strength. Revisit FHLC’s defensive role if its largest holdings materially cut outlooks or broad healthcare fundamentals deteriorate.